Skip to main content
ATNM
NYSE Life Sciences

Actinium Q3 Loss Widens to $5.8M; Cash Falls to $28.7M With 12-Month Runway

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Negative
Importance info
7
Price
$1.12
Mkt Cap
$33.957M
52W Low
$0.735
52W High
$1.72
52W Position info
52% above low
Off High info
35% below high
Rel. Volume info
1.7× avg
Market data snapshot near publication time

ATNM sits 52% above its 52-week low of $0.735.

Summary

Actinium's Q3 loss widened to $5.8 million and cash fell to $28.7 million, while a one-time $35.0 million deferred-revenue recognition produced a $16.5 million nine-month profit and lifted equity to $24.6 million, back above the NYSE American minimum.


Key Events · Earnings and Guidance · ATNM

  • Q3 Loss Widens, Nine-Month Profit Is One-Time

    Q3 2026 net loss was $5.8 million versus $5.1 million a year earlier. The $16.5 million nine-month profit stems from June 2026 recognition of a $35.0 million deferred Immedica upfront payment that will not recur.

  • Cash Falls to $28.7 Million

    Cash and equivalents dropped to $28.7 million at September 30, 2026 from $48.0 million at December 31, 2025, with $18.1 million used in operations over nine months. Management expects resources to fund operations for more than 12 months.

  • Equity Rebuilt Above NYSE American Minimum

    Stockholders' equity rose to $24.6 million from $2.3 million at March 31, 2026, clearing the $4.0 million NYSE American threshold behind the May 27, 2026 deficiency notice; the compliance plan period runs to November 27, 2027.

  • New CFO and Executive Contracts

    Matt David began as CFO on October 14, 2026, and the CEO, CSO and CMO entered amended and restated employment agreements dated November 12, 2026.


Analysis · ATNM · Life Sciences

The headline $16.5 million nine-month profit is an accounting artifact: it comes entirely from recognizing a $35.0 million Immedica upfront payment that had been deferred since 2022, after the company concluded Immedica's claim to it had expired. That item will not recur, and the underlying business still burns cash — $18.1 million used in operations over nine months, leaving $28.7 million at September 30 versus $48.0 million at year-end. Management says that cash funds planned operations for more than 12 months, which buys time but leaves little room before another raise. The offsetting positive is balance sheet repair: stockholders' equity climbed to $24.6 million from $2.3 million at March 31, 2026, well above the $4.0 million NYSE American threshold that triggered the May 2026 deficiency notice, with the plan period running to November 27, 2027. Also new: a CFO started October 14, 2026, and the CEO, CSO and CMO signed amended employment agreements on November 12, 2026, and the company disclosed a July 31, 2026 Novartis letter demanding it pull preclinical ATNM-400 comparisons to Pluvicto.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ATNM was trading at $1.12 on NYSE in the Life Sciences sector, with a market capitalization of approximately $34M. The 52-week trading range was $0.74 to $1.72. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ATNM - Latest Insights